InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the stock.

Separately, Lake Street Capital started coverage on InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price for the company.

InspireMD Stock Performance

NYSE NSPR opened at $3.19 on Friday. The business has a 50 day simple moving average of $2.78 and a 200 day simple moving average of $2.74. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42. The stock has a market cap of $83.21 million, a price-to-earnings ratio of -4.25 and a beta of 1.00.

Hedge Funds Weigh In On InspireMD

A number of large investors have recently bought and sold shares of NSPR. Parkman Healthcare Partners LLC boosted its position in InspireMD by 721.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock worth $2,248,000 after acquiring an additional 750,635 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in InspireMD during the 4th quarter worth approximately $191,000. Northern Trust Corp boosted its position in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after acquiring an additional 24,452 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its position in InspireMD by 153.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after acquiring an additional 18,233 shares during the last quarter. Finally, Legato Capital Management LLC acquired a new position in InspireMD during the 4th quarter worth approximately $47,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.